low-to-moderate - Medical devices and diagnostics have non-discretionary healthcare demand with hospital procedure volumes showing resilience except during severe recessions. Nutritional products (infant formula, adult nutrition) are relatively stable. Established pharmaceuticals in emerging markets show moderate GDP sensitivity as middle-class expansion drives healthcare spending. Elective procedures (some cardiovascular interventions) can see modest deferrals during economic stress but diabetes care is highly recurring and non-cyclical.

Low direct sensitivity as Abbott carries modest debt (0.25x D/E) with $3-4B annual free cash flow covering interest expense comfortably. Higher rates modestly pressure valuation multiples for healthcare growth stocks but less than high-duration sectors. Emerging market currencies can weaken during Fed tightening cycles, creating FX translation headwinds on international revenue. Hospital capital equipment purchases may face modest financing cost pressure but medical device demand is largely rate-insensitive.

dividend-growth - Abbott is a Dividend Aristocrat with 52 consecutive years of dividend increases, attracting income-focused investors. Also appeals to healthcare growth investors given FreeStyle Libre's double-digit growth trajectory and medical device innovation pipeline. Defensive characteristics during market volatility given non-cyclical healthcare demand. Recent 50%+ earnings decline reflects COVID testing normalization, creating value opportunity as base business growth re-accelerates.